Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: The impact of late referral

Background: Oral drugs have made the treatment of pulmonary hypertension (PH) feasible in non-expert centers, which could delay patient access to prostanoid therapy. Methods: Fifty-seven consecutive patients with precapillary PH received a prostanoid in our center. Data at prostanoid initiation included modality of center referral, medical history, New York Heart Association [NYHA] class, exercise capacity, echocardiographic parameters, and hemodynamics. Results: Overall survival at 1, 2, and 3 years was 85%, 69%, 55%, respectively. Non-survivors had worse NYHA class III/IV (17/12) than survivors (27/1; p <0.01) and exercise capacity on 6-minute-walk distance (254 ± 114 vs 354 ± 91 meters; p <0.01). Non-survivors were more frequently referred on oral therapy (83% vs 36%; p <0.01) and had a higher rate of urgent prostanoid treatment (69% vs 17%; p <0.0001). Multivariate analysis (hazard ratio [95% confidence interval]) found the independent prognostic factors were urgent prostanoid therapy (2.0 [1.13.9]) and NYHA class (3.5 [1.58.2]). Survivors had a significant response to prostanoid, improving NYHA class from 2.8 ± 0.4 to 2.3 ± 0.5 (p = 0.002), 6-minute walk distance from 354 ± 91 to 426 ± 82 meters (p = 0.0001), and pulmonary hemodynamics (pulmonary artery pressure from 56 ± 13 to 44 ± 18 mm Hg [p <0.05]; cardiac index from 2.0 ± 1.2 to 3.1 ± 1.2 liters/min/m ² [p = 0.002], and pulmonary vascular resistance from 17 ± 10 to 8 ± 6 WU [p = 0.001]). Conclusions: Referral of patients on oral treatment to a tertiary PH center is delayed and significantly affects prognosis.